KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Receivables (2016 - 2025)

Historic Receivables for Rigel Pharmaceuticals (RIGL) over the last 12 years, with Q3 2025 value amounting to $46.0 million.

  • Rigel Pharmaceuticals' Receivables rose 5039.08% to $46.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $46.0 million, marking a year-over-year increase of 5039.08%. This contributed to the annual value of $41.6 million for FY2024, which is 3621.93% up from last year.
  • Per Rigel Pharmaceuticals' latest filing, its Receivables stood at $46.0 million for Q3 2025, which was up 5039.08% from $40.0 million recorded in Q2 2025.
  • Rigel Pharmaceuticals' Receivables' 5-year high stood at $142.2 million during Q1 2021, with a 5-year trough of $3.1 million in Q1 2025.
  • For the 5-year period, Rigel Pharmaceuticals' Receivables averaged around $30.5 million, with its median value being $23.5 million (2023).
  • As far as peak fluctuations go, Rigel Pharmaceuticals' Receivables surged by 137199.79% in 2021, and later crashed by 8928.23% in 2022.
  • Over the past 5 years, Rigel Pharmaceuticals' Receivables (Quarter) stood at $15.5 million in 2021, then rose by 29.27% to $20.0 million in 2022, then skyrocketed by 52.75% to $30.6 million in 2023, then skyrocketed by 36.22% to $41.6 million in 2024, then grew by 10.49% to $46.0 million in 2025.
  • Its Receivables was $46.0 million in Q3 2025, compared to $40.0 million in Q2 2025 and $3.1 million in Q1 2025.